{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T08:10:26Z","timestamp":1737706226484,"version":"3.33.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Korea Research Institute of Bioscience & Biotechnology (KRIBB) Research Initiative Program","award":["KGM9942421"],"award-info":[{"award-number":["KGM9942421"]}]},{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["2020R1A2C2101964"],"award-info":[{"award-number":["2020R1A2C2101964"]}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["HI23C0392"],"award-info":[{"award-number":["HI23C0392"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03100-y","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:52:46Z","timestamp":1737701566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants"],"prefix":"10.1186","volume":"23","author":[{"given":"Jaehyeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumin","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hyeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonbeom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjoo","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soomin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokhyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangwon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Taek","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Jick","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Hyuk","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3100_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","volume":"12","author":"A Gharbharan","year":"2021","unstructured":"Gharbharan A, Jordans CC, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FP, Stalenhoef-Schukken JE, Dofferhoff A, Ludwig I, Koster A. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12:3189.","journal-title":"Nat Commun"},{"key":"3100_CR2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582\u20139.","journal-title":"JAMA"},{"key":"3100_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/infdis\/jiab377","volume":"224","author":"R Ganesh","year":"2021","unstructured":"Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, DestroBorgen MJ, Hanson SN, Kennedy BD. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis. 2021;224:1278\u201386.","journal-title":"J Infect Dis"},{"key":"3100_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac186","author":"MM Al-Obaidi","year":"2022","unstructured":"Al-Obaidi MM, Gungor AB, Nematollahi S, Zangeneh TT, Bedrick EJ, Johnson KM, Low-Adegbija NE, Alam R, Rangan P, WilliamHeise C. Effectiveness of casirivimab-imdevimab monoclonal antibody treatment among high-risk patients with severe acute respiratory syndrome coronavirus 2 B. 1.617.2 (Delta variant) infection. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac186.","journal-title":"Open Forum Infect Dis"},{"key":"3100_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.abc5881","volume":"369","author":"Z Lv","year":"2020","unstructured":"Lv Z, Deng Y-Q, Ye Q, Cao L, Sun C-Y, Fan C, Huang W, Sun S, Sun Y, Zhu L. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505\u20139.","journal-title":"Science"},{"key":"3100_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593\u2013602.","journal-title":"Nature"},{"key":"3100_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.chom.2022.05.001","volume":"30","author":"J Ai","year":"2022","unstructured":"Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30:1077-1083.e4.","journal-title":"Cell Host Microbe"},{"key":"3100_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.chom.2022.09.018","volume":"30","author":"Y Cao","year":"2022","unstructured":"Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Cell Host Microbe. 2022;30:1527-1539.e5.","journal-title":"Cell Host Microbe"},{"key":"3100_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553\u20136.","journal-title":"Nature"},{"key":"3100_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279-286.e8.","journal-title":"Cell"},{"key":"3100_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","volume":"23","author":"C Yue","year":"2023","unstructured":"Yue C, Song W, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X, Cao Y. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23:278\u201380.","journal-title":"Lancet Infect Dis"},{"key":"3100_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMc2120219","volume":"386","author":"R Rockett","year":"2022","unstructured":"Rockett R, Basile K, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, Arnott A, Chandra S, Gall M, Draper J. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N Engl J Med. 2022;386:1477\u20139.","journal-title":"N Engl J Med"},{"key":"3100_CR13","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/cts.13384","volume":"15","author":"SH Yoo","year":"2022","unstructured":"Yoo SH, Kim L, Lu M, Nagoshi K, Namchuk MN. A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics. Clin Transl Sci. 2022;15:2279\u201392.","journal-title":"Clin Transl Sci"},{"key":"3100_CR14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41589-022-01140-1","volume":"18","author":"PA-B Weidenbacher","year":"2022","unstructured":"Weidenbacher PA-B, Waltari E, RiosKobara de Los I, Bell BN, Morris MK, Cheng Y-C, Hanson C, Pak JE, Kim PS. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat Chem Biol. 2022;18:1270\u20136.","journal-title":"Nat Chem Biol"},{"key":"3100_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-024-07385-1","volume":"629","author":"TA Desautels","year":"2024","unstructured":"Desautels TA, Arrildt KT, Zemla AT, Lau EY, Zhu F, Ricci D, Cronin S, Zost SJ, Binshtein E, Scheaffer SM. Computationally restoring the potency of a clinical antibody against Omicron. Nature. 2024;629:1\u20138.","journal-title":"Nature"},{"key":"3100_CR16","doi-asserted-by":"publisher","first-page":"109363","DOI":"10.1016\/j.isci.2024.109363","volume":"27","author":"T Inoue","year":"2024","unstructured":"Inoue T, Yamamoto Y, Sato K, Okemoto-Nakamura Y, Shimizu Y, Ogawa M, Onodera T, Takahashi Y, Wakita T, Kaneko MK. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies. iScience. 2024;27:109363.","journal-title":"iScience"},{"key":"3100_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-00997-x","volume":"7","author":"Y Fan","year":"2022","unstructured":"Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:1\u201311.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng B, Abdullahi A, Ferreira IA, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706\u201314.","journal-title":"Nature"},{"key":"3100_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/22221751.2021.2023329","volume":"11","author":"H Zhao","year":"2022","unstructured":"Zhao H, Lu L, Peng Z, Chen L-L, Meng X, Zhang C, Ip JD, Chan W-M, Chu AW-H, Chan K-H. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277\u201383.","journal-title":"Emerg Microbes Infect"},{"key":"3100_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2022.11.006","volume":"44","author":"MY Chow","year":"2023","unstructured":"Chow MY, Pan HW, Seow HC, Lam JK. Inhalable neutralizing antibodies\u2013promising approach to combating respiratory viral infections. Trends Pharmacol Sci. 2023;44:85\u201397.","journal-title":"Trends Pharmacol Sci"},{"key":"3100_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41392-023-01656-5","volume":"8","author":"X Li","year":"2023","unstructured":"Li X, Peng P, Deng H, Yang Q, Chen S, Li B, He M, Jin A, Yang Z, Tang N. Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19. Signal Transduct Target Ther. 2023;8:403.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR22","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1093\/cid\/ciac448","volume":"76","author":"Y Lin","year":"2023","unstructured":"Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X, Gao L, Zhou J, Li Z, Hu L. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: a small-scale clinical trial. Clin Infect Dis. 2023;76:e336\u201341.","journal-title":"Clin Infect Dis"},{"key":"3100_CR23","doi-asserted-by":"publisher","first-page":"2294860","DOI":"10.1080\/22221751.2023.2294860","volume":"13","author":"A Patel","year":"2024","unstructured":"Patel A, Rosenke K, Parzych EM, Feldmann F, Bharti S, Griffin AJ, Schouest B, Lewis M, Choi J, Chokkalingam N. In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates. Emerg Microbes Infect. 2024;13:2294860.","journal-title":"Emerg Microbes Infect"},{"key":"3100_CR24","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1038\/s41467-021-26354-0","volume":"12","author":"P Maisonnasse","year":"2021","unstructured":"Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gon\u00e7alves A, Caniels TG. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nat Commun. 2021;12:6097.","journal-title":"Nat Commun"},{"key":"3100_CR25","doi-asserted-by":"publisher","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"Y-M Loo","year":"2022","unstructured":"Loo Y-M, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, Flores DJ, Kelly EJ, Ren K, Roque R. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14:eabl8124.","journal-title":"Sci Transl Med."},{"key":"3100_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.medj.2022.01.004","volume":"3","author":"RR Cobb","year":"2022","unstructured":"Cobb RR, Nkolola J, Gilchuk P, Chandrashekar A, Yu J, House RV, Earnhart CG, Dorsey NM, Hopkins SA, Snow DM. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med. 2022;3:188-203.e4.","journal-title":"Med"},{"key":"3100_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s11095-022-03340-9","volume":"39","author":"J Jia","year":"2022","unstructured":"Jia J, Yin Z, Zhang X, Li H, Meng D, Liu Q, Wang H, Han M, Suo S, Liu Y. Feasibility studies of nebulized SARS-CoV-2 neutralizing antibody in mice and cynomolgus monkeys. Pharm Res. 2022;39:2191\u2013201.","journal-title":"Pharm Res"},{"key":"3100_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mai.2001.116576","volume":"108","author":"TK Hart","year":"2001","unstructured":"Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108:250\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"3100_CR29","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.1038\/s41467-023-42440-x","volume":"14","author":"DN Streblow","year":"2023","unstructured":"Streblow DN, Hirsch AJ, Stanton JJ, Lewis AD, Colgin L, Hessell AJ, Kreklywich CN, Smith JL, Sutton WF, Chauvin D. Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. Nat Commun. 2023;14:7062.","journal-title":"Nat Commun"},{"key":"3100_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nmat5053","volume":"17","author":"V Cagno","year":"2018","unstructured":"Cagno V, Andreozzi P, Dalicarnasso M, Jacob Silva P, Mueller M, Galloux M, Le Goffic R, Jones ST, Vallino M, Hodek J, Weber J, Sen S, Janecek ER, Bekdemir A, Sanavio B, Martinelli C, Donalisio M, Rameix Welti MA, Eleouet JF, Han Y, Kaiser L, Vukovic L, Tapparel C, Kral P, Krol S, Lembo D, Stellacci F. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018;17:195\u2013203.","journal-title":"Nat Mater"},{"key":"3100_CR31","doi-asserted-by":"publisher","first-page":"13146","DOI":"10.1021\/jacs.2c02764","volume":"144","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xu Y, Huang Y, Wang H, Gong X, Wei K. Spatially patterned neutralizing icosahedral DNA nanocage for efficient SARS-CoV-2 blocking. J Am Chem Soc. 2022;144:13146\u201353.","journal-title":"J Am Chem Soc"},{"key":"3100_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310469121","volume":"121","author":"R Gao","year":"2024","unstructured":"Gao R, Xu X, Kumar P, Liu Y, Zhang H, Guo X, Sun M, Colombari FM, de Moura AF, Hao C. Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for SARS-CoV-2 variants. Proc Natl Acad Sci USA. 2024;121: e2310469121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3100_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41467-018-08138-1","volume":"10","author":"B Kong","year":"2019","unstructured":"Kong B, Moon S, Kim Y, Heo P, Jung Y, Yu S-H, Chung J, Ban C, Kim YH, Kim P. Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. Nat Commun. 2019;10:185.","journal-title":"Nat Commun"},{"key":"3100_CR34","doi-asserted-by":"publisher","first-page":"36757","DOI":"10.1021\/acsami.1c06364","volume":"13","author":"H Oh","year":"2021","unstructured":"Oh H, Jung Y, Moon S, Hwang J, Ban C, Chung J, Chung W-J, Kweon D-H. Development of end-spliced dimeric nanodiscs for the improved virucidal activity of a nanoperforator. ACS Appl Mater Interfaces. 2021;13:36757\u201368.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3100_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2022.102587","volume":"44","author":"S Moon","year":"2022","unstructured":"Moon S, Chung J, Kim Y, Hong C, Kim S, Hwang J, Jung Y, Chung W-J, Kweon D-H. Bifunctional hetero di-disc for broad-spectrum influenza neutralization. NBM. 2022;44: 102587.","journal-title":"NBM"},{"key":"3100_CR36","doi-asserted-by":"publisher","first-page":"2470091","DOI":"10.1002\/adhm.202470091","volume":"13","author":"J Hwang","year":"2024","unstructured":"Hwang J, Kim BK, Moon S, Park W, Kim KW, Yoon JH, Oh H, Jung S, Park Y, Kim S. Conversion of host cell receptor into virus destructor by immunodisc to neutralize diverse SARS-CoV-2 variants. Adv Healthc Mater. 2024;13:2470091.","journal-title":"Adv Healthc Mater"},{"key":"3100_CR37","doi-asserted-by":"publisher","first-page":"2101516","DOI":"10.1002\/smtd.202101516","volume":"6","author":"J Hwang","year":"2022","unstructured":"Hwang J, Jung Y, Moon S, Yu S, Oh H, Kim S, Kim KW, Yoon JH, Chun J, Kim SJ. Nanodisc-mediated conversion of virustatic antiviral antibody to disrupt virus envelope in infected cells. Small Methods. 2022;6:2101516.","journal-title":"Small Methods"},{"key":"3100_CR38","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1021\/acs.chemrev.6b00690","volume":"117","author":"IG Denisov","year":"2017","unstructured":"Denisov IG, Sligar SG. Nanodiscs in membrane biochemistry and biophysics. Chem Rev. 2017;117:4669\u2013713.","journal-title":"Chem Rev"},{"key":"3100_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105591","volume":"213","author":"S Son","year":"2023","unstructured":"Son S, Ahn SB, Kim G, Jang Y, Ko C, Kim M, Kim SJ. Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice. Antiviral Res. 2023;213: 105591.","journal-title":"Antiviral Res"},{"key":"3100_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6750-12-62","volume":"12","author":"H Yoon","year":"2012","unstructured":"Yoon H, Song JM, Ryu CJ, Kim Y-G, Lee EK, Kang S, Kim SJ. An efficient strategy for cell-based antibody library selection using an integrated vector system. BMC Biotechnol. 2012;12:1\u201310.","journal-title":"BMC Biotechnol"},{"key":"3100_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/protein\/gzv065","volume":"29","author":"C Barinka","year":"2016","unstructured":"Barinka C, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA). Protein Eng Des Sel. 2016;29:105\u201315.","journal-title":"Protein Eng Des Sel"},{"key":"3100_CR42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1126\/science.287.5456.1279","volume":"287","author":"WL DeLano","year":"2000","unstructured":"DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein-protein interface. Science. 2000;287:1279\u201383.","journal-title":"Science"},{"key":"3100_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115\u20139.","journal-title":"Nature"},{"key":"3100_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41589-021-00924-1","volume":"18","author":"L Nguyen","year":"2022","unstructured":"Nguyen L, McCord KA, Bui DT, Bouwman KM, Kitova EN, Elaish M, Kumawat D, Daskhan GC, Tomris I, Han L. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. Nat Chem Biol. 2022;18:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"3100_CR45","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/acsinfecdis.3c00106","volume":"9","author":"G Negi","year":"2023","unstructured":"Negi G, Sharma A, Chaudhary M, Gupta D, Harshan KH, Parveen N. SARS-CoV-2 binding to terminal sialic acid of gangliosides embedded in lipid membranes. ACS Infect Dis. 2023;9:1346\u201361.","journal-title":"ACS Infect Dis"},{"key":"3100_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/acsinfecdis.3c00519","volume":"10","author":"M Dey","year":"2024","unstructured":"Dey M, Sharma A, Dhanawat G, Gupta D, Harshan KH, Parveen N. Synergistic binding of SARS-CoV-2 to ACE2 and gangliosides in native lipid membranes. ACS Infect Dis. 2024;10:907\u201316.","journal-title":"ACS Infect Dis"},{"key":"3100_CR47","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"3100_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030237","volume":"3","author":"J ter Meulen","year":"2006","unstructured":"ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, Goudsmit J. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3: e237.","journal-title":"PLoS Med"},{"key":"3100_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan M, Wu NC, Zhu X, Lee C-CD, So RT, Lv H, Mok CK, Wilson IA. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368:630\u20133.","journal-title":"Science"},{"key":"3100_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014\u20138.","journal-title":"Science"},{"key":"3100_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290\u20135.","journal-title":"Nature"},{"key":"3100_CR52","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","volume":"621","author":"A Addetia","year":"2023","unstructured":"Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, Dang H, de Melo GD, Pinto D, Sprouse K, Scheaffer SM, Bassi J, Silacci-Fregni C, Muoio F, Dini M, Vincenzetti L, Acosta R, Johnson D, Subramanian S, Saliba C, Giurdanella M, Lombardo G, Leoni G, Culap K, McAlister C, Rajesh A, Dellota E Jr, Zhou J, Farhat N, Bohan D, Noack J, Chen A, Lempp FA, Quispe J, Kergoat L, Larrous F, Cameroni E, Whitener B, Giannini O, Cippa P, Ceschi A, Ferrari P, Franzetti-Pellanda A, Biggiogero M, Garzoni C, Zappi S, Bernasconi L, Kim MJ, Rosen LE, Schnell G, Czudnochowski N, Benigni F, Franko N, Logue JK, Yoshiyama C, Stewart C, Chu H, Bourhy H, Schmid MA, Purcell LA, Snell G, Lanzavecchia A, Diamond MS, Corti D, Veesler D. Neutralization, effector function and immune imprinting of Omicron variants. Nature. 2023;621:592\u2013601.","journal-title":"Nature"},{"key":"3100_CR53","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A. Distinct evolution of SARS-CoV-2 Omicron XBB and BA 2.86\/JN 1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024;15:2254.","journal-title":"Nat Commun"},{"key":"3100_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","volume":"23","author":"P Arora","year":"2023","unstructured":"Arora P, Kempf A, Nehlmeier I, Schulz SR, J\u00e4ck H-M, P\u00f6hlmann S, Hoffmann M. Omicron sublineage BQ 11 resistance to monoclonal antibodies. Lancet Infect Dis. 2023;23:22\u20133.","journal-title":"Lancet Infect Dis"},{"key":"3100_CR55","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41467-024-49096-1","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hao A, Ji P, Ma Y, Zhang Z, Chen J, Mao Q, Xiong X, Rehati P, Wang Y. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB. 1.16, BQ. 1.1 and sarbecoviruses. Nat Commun. 2024;15:5127.","journal-title":"Nat Commun"},{"key":"3100_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Duan Y, Gong K, Xu S, Wang X, Zhang L, Li J, Huang F, Zhao Y, Zhu L, Li W, Huang Y. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7:265.","journal-title":"Signal Transduct Target Ther"},{"key":"3100_CR57","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","volume":"10","author":"R Kuai","year":"2016","unstructured":"Kuai R, Li D, Chen YE, Moon L, Schwendeman T, Parhami JJ, Knudsen KL, Helmus B, Schnitzer TW. High-density lipoproteins: nature\u2019s multifunctional nanoparticles. ACS Nano. 2016;10:3015\u201341.","journal-title":"ACS Nano"},{"key":"3100_CR58","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/MOL.0000000000000020","volume":"24","author":"BR Krause","year":"2013","unstructured":"Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013;24:480\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"3100_CR59","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","volume":"134","author":"C MichaelGibson","year":"2016","unstructured":"MichaelGibson C, Korjian S, Tricoci P, Brown EA, Alexander M, Hernandez AM, Abraham MT, Lytle TJ, Veledar DP, Bhatt DL. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016;134:1918\u201330.","journal-title":"Circulation"},{"key":"3100_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ehjcvp\/pvv041","volume":"2","author":"DG Kallend","year":"2016","unstructured":"Kallend DG, Reijers JAA, Bellibas SE, Bobillier A, Kempen H, Burggraaf J, Moerland M, Wijngaard PLJ. A single infusion of MDCO-216 (ApoA-1 Milano\/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur Heart J Cardiovasc Pharmacother. 2016;2:23\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:41:54Z","timestamp":1737704514000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3100"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03100-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics and Consent to Participate declarations: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}